JP2021525729A5 - - Google Patents

Info

Publication number
JP2021525729A5
JP2021525729A5 JP2020566655A JP2020566655A JP2021525729A5 JP 2021525729 A5 JP2021525729 A5 JP 2021525729A5 JP 2020566655 A JP2020566655 A JP 2020566655A JP 2020566655 A JP2020566655 A JP 2020566655A JP 2021525729 A5 JP2021525729 A5 JP 2021525729A5
Authority
JP
Japan
Prior art keywords
composition
sepiapterin
subject
effective amount
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525729A (ja
JP7502197B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034523 external-priority patent/WO2019232130A1/en
Publication of JP2021525729A publication Critical patent/JP2021525729A/ja
Publication of JP2021525729A5 publication Critical patent/JP2021525729A5/ja
Priority to JP2024015822A priority Critical patent/JP7841005B2/ja
Application granted granted Critical
Publication of JP7502197B2 publication Critical patent/JP7502197B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566655A 2018-05-30 2019-05-30 セピアプテリン血漿曝露を増加させるための方法 Active JP7502197B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024015822A JP7841005B2 (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862677943P 2018-05-30 2018-05-30
US62/677,943 2018-05-30
US201862771398P 2018-11-26 2018-11-26
US62/771,398 2018-11-26
US201962822376P 2019-03-22 2019-03-22
US62/822,376 2019-03-22
GC2019-37663 2019-05-28
GC201937663 2019-05-28
PCT/US2019/034523 WO2019232130A1 (en) 2018-05-30 2019-05-30 Methods for increasing sepiapterin plasma exposure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024015822A Division JP7841005B2 (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Publications (3)

Publication Number Publication Date
JP2021525729A JP2021525729A (ja) 2021-09-27
JP2021525729A5 true JP2021525729A5 (cg-RX-API-DMAC7.html) 2022-06-03
JP7502197B2 JP7502197B2 (ja) 2024-06-18

Family

ID=68699037

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566655A Active JP7502197B2 (ja) 2018-05-30 2019-05-30 セピアプテリン血漿曝露を増加させるための方法
JP2024015822A Active JP7841005B2 (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024015822A Active JP7841005B2 (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Country Status (20)

Country Link
US (3) US11617752B2 (cg-RX-API-DMAC7.html)
EP (2) EP3801536B1 (cg-RX-API-DMAC7.html)
JP (2) JP7502197B2 (cg-RX-API-DMAC7.html)
CN (1) CN112703002A (cg-RX-API-DMAC7.html)
AU (2) AU2019277382B2 (cg-RX-API-DMAC7.html)
CA (1) CA3102106A1 (cg-RX-API-DMAC7.html)
DK (1) DK3801536T3 (cg-RX-API-DMAC7.html)
ES (1) ES2986920T3 (cg-RX-API-DMAC7.html)
FI (1) FI3801536T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241213T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068589T2 (cg-RX-API-DMAC7.html)
LT (1) LT3801536T (cg-RX-API-DMAC7.html)
MD (1) MD3801536T2 (cg-RX-API-DMAC7.html)
MX (2) MX2020012979A (cg-RX-API-DMAC7.html)
PL (1) PL3801536T3 (cg-RX-API-DMAC7.html)
PT (1) PT3801536T (cg-RX-API-DMAC7.html)
RS (1) RS65874B1 (cg-RX-API-DMAC7.html)
SI (1) SI3801536T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400430T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019232130A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
CA3165636A1 (en) * 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
WO2021168206A1 (en) * 2020-02-19 2021-08-26 Musc Foundation For Research Development L-sepiapterin and methods of use for treating diseases and disorders
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
IL305037A (en) * 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
CN120732846A (zh) * 2025-04-09 2025-10-03 中南大学湘雅医院 吲哚乙酸在制备预防或治疗高血压产品中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
WO1997007236A1 (en) 1995-08-18 1997-02-27 Landry Donald W Detection of organic compounds through regulation of antibody-catalyzed reactions
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
CA2545968C (en) 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
CN101132776A (zh) 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
KR20160065998A (ko) * 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
JP5066756B2 (ja) 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
JP6084967B2 (ja) 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
EP3213062B1 (en) * 2014-10-31 2020-02-12 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CN111328414B (zh) * 2017-11-23 2022-09-23 株式会社半导体能源研究所 显示装置及电子设备
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (en) * 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Similar Documents

Publication Publication Date Title
JP2024069192A5 (cg-RX-API-DMAC7.html)
FI3801536T3 (fi) Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
JP2024063143A5 (cg-RX-API-DMAC7.html)
JP2021525746A5 (cg-RX-API-DMAC7.html)
TW200838545A (en) Therapeutic agent for painful disease
RU2010121827A (ru) Композиции для лечения болезни паркинсона
JP2015519404A5 (cg-RX-API-DMAC7.html)
JP2013544887A5 (cg-RX-API-DMAC7.html)
FI3801534T3 (fi) Fenyyliketonurian hoito sepiapteriinilla
JP2020513032A5 (cg-RX-API-DMAC7.html)
JP2022507533A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
JP2022514537A5 (cg-RX-API-DMAC7.html)
US20260053808A1 (en) Novel uses
JP6704252B2 (ja) 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬
RU2009119258A (ru) Способ лечения воспалительных заболеваний кишечника
JP2018531273A5 (cg-RX-API-DMAC7.html)
JP2020521726A5 (cg-RX-API-DMAC7.html)
US20030195255A1 (en) Method for treating hepatic encephalopathies
KR20180034442A (ko) 아캄프로세이트와 d-사이클로세린을 사용한 병용 치료
JP2023553253A5 (cg-RX-API-DMAC7.html)
CN113784717A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2023541007A5 (cg-RX-API-DMAC7.html)
JP2019507786A5 (cg-RX-API-DMAC7.html)
JP2020531543A (ja) アマンタジン組成物、その調製、および使用方法